leukemia

— Potential for durable responses with alternative antigen-targeted therapy A promising new treatment targeting a different antigen has shown success among patients with large B-cell lymphoma who previously relapsed after receiving CD19-directed CAR T-cell therapy (CAR19), according to findings from a phase I dose-finding study. In the study, 38 patients who had not responded to CAR19 achieved a 68% overall response rate and a 53% complete response rate following treatment with autologous

Recent studies indicate that engaging in moderate to vigorous physical activity may enhance the effectiveness of rituximab, a monoclonal antibody therapy used in treating chronic lymphocytic leukemia (CLL). Researchers based in England discovered that such exercise prompted a rise in natural killer cells, which, when combined with rituximab, help target and destroy cancerous cells in the bloodstream. Although experts acknowledge the growing evidence suggesting the immune-boosting capacity of